NOD2 gain-of-function mutations leading to uncontrolled NF-κB activation are found in severe autoinflammatory disorders like early-onset sarcoidosis (EOS) and Blau syndrome (BS) [11], underscoring the need to tightly regulate NOD2 activation. Here, NFKB1 is linked to Blau syndrome.